Home » GLAXOSMITHKLINE REPORTS POSITIVE DRUG TRIAL RESULTS

GLAXOSMITHKLINE REPORTS POSITIVE DRUG TRIAL RESULTS

June 19, 2006

UK-based pharmaceutical major GlaxoSmithKline Plc Monday reported encouraging results of the phase III clinical trials of its experimental drug, eltrombopag. The drug was researched in collaboration with Ligand Pharmaceuticals.
Newratings

KEYWORDS Daily International Pharma Alert

07Dec
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
08Dec
Simplifying Oncology Trials: Make the Most of Remote Monitoring and Decentralization
08Dec
Extractables and Leachables: Taking a Deeper Dive
09Dec
Drug Safety Reporting Requirements: Best Practices for Monitoring, Reporting and Avoiding Regulatory Missteps
15Dec
Promoting & Marketing in the Digital and Virtual World: What Regulatory, Compliance & Marketing Professionals Need to Know

GLAXOSMITHKLINE REPORTS POSITIVE DRUG TRIAL RESULTS

Upcoming Events

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Simplifying Oncology Trials: Make the Most of Remote Monitoring and Decentralization

Extractables and Leachables: Taking a Deeper Dive

Drug Safety Reporting Requirements: Best Practices for Monitoring, Reporting and Avoiding Regulatory Missteps

Promoting & Marketing in the Digital and Virtual World: What Regulatory, Compliance & Marketing Professionals Need to Know

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

FDA Rejects BeyondSpring’s NDA for Neutropenia Therapy

AMF Medical’s Sigi Insulin System Designated an FDA Breakthrough Device

Novavax to Develop Omicron-Specific COVID-19 Shot

Qiagen and DiaSorin Gain Premarket Approval for TB Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements